论文部分内容阅读
目的：探讨纤支镜肺癌标本中肿瘤标记物的表达及其与预后的关系。方法：应用增生细胞核抗原（ＰＣＮＡ）、ｒａｓ－ｐ２１、ｐ５３单克隆抗体和ｃ－ｅｒｂＢ－２多克隆抗体，对７１例肺癌的纤支镜标本和１０例正常肺组织进行免疫组化染色研究。结果：１０例正常肺组织均为阴性表达。７１例肺癌中，ＰＣＮＡ、ｒａｓ－ｐ２１、ｐ５３、ｃ－ｅｒｂＢ－２抗体的阳性表达率分别为：７０．４２％；８０．２８％；５６．３４％和８１．６９％。ｃ－ｅｒｂＢ－２与肺癌分型相关，其它三者与肺癌分型、分化及ＴＮＭ分期无关。但与预后均呈负相关。结论：上述４种抗体可作为判断肺癌预后的肿瘤标记物，提示用于术前判定肺癌患者的预后是可行的。
Objective: To investigate the expression of tumor markers in bronchoscopic lung cancer specimens and its relationship with prognosis. METHODS: Immunohistochemical staining of bronchoscopic specimens and normal lung tissues from 71 patients with lung cancer was performed using PCNA, ras-p21, p53 monoclonal antibody, and c-erbB-2 polyclonal antibody. Results: 10 cases of normal lung tissue were negative expression. In 71 cases of lung cancer, the positive expression rates of PCNA, ras-p21, p53 and c-erbB-2 antibodies were 70.42%, 80.28%, 56.34% and 81.69%, respectively. C-erbB-2 was associated with lung cancer classification, and the other three were not related to lung cancer type, differentiation and TNM staging. However, it has a negative correlation with the prognosis. Conclusion: The above four antibodies can be used as tumor markers for judging the prognosis of lung cancer, suggesting that it is feasible to determine the prognosis of lung cancer patients before surgery.